Is BMY a Buy? What to Consider in 2026
Last updated June 2026
Short answer
There is no universal answer to whether BMY is a buy; it depends on your thesis, time horizon, and what you already own. Below is the case for Bristol Myers Squibb, the main risks to weigh, where the stock trades, and a framework to decide for yourself. This is informational, not a recommendation, and Walnut is not an investment adviser.
Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. It makes money primarily by selling patented branded drugs, with a portfolio that has historically leaned on blockbuster franchises such as the blood thinner Eliquis (co-marketed with Pfizer), the cancer immunotherapy Opdivo, and the multiple myeloma drug Revlimid. The company is navigating a major patent cliff as several legacy products lose exclusivity, and it is rebuilding growth through a newer portfolio that includes drugs like Reblozyl, Opdualag, Camzyos, Sotyktu, and the schizophrenia treatment Cobenfy (acquired through Karuna). Bristol Myers grows both organically through its research pipeline and through large acquisitions (Celgene, MyoKardia, Karuna, Mirati). It is headquartered in New York and operates worldwide.
The case for Bristol Myers Squibb
1. New product portfolio ramp.
Bristol Myers is shifting revenue weight toward a newer set of growth drivers including Reblozyl, Opdualag, Camzyos, Breyanzi, Sotyktu, and Cobenfy. Management frames these as the engine meant to offset legacy patent losses. The success of this transition, especially Cobenfy in neuropsychiatry, is central to the multi-year growth story and to whether the company can return to durable top-line expansion.
2. Oncology and immunology depth.
The company has a deep oncology franchise anchored by Opdivo plus cell therapies (Breyanzi, Abecma) and a broad immunology effort led by the oral psoriasis drug Sotyktu. Expanding indications, subcutaneous formulations (Opdivo Qvantig), and combination regimens can extend the life and reach of these franchises, supporting revenue even as older products fade.
3. Pipeline and disciplined dealmaking.
Bristol Myers has a history of large, focused acquisitions (Celgene, MyoKardia, Karuna, Mirati, RayzeBio) to add pipeline assets and new modalities such as radiopharmaceuticals. A productive late-stage pipeline plus targeted business development is how the company aims to replenish revenue and address the looming exclusivity losses on its biggest legacy products.
4. Strong cash generation.
The branded pharma model produces substantial free cash flow, which funds a meaningful dividend, share repurchases, debt reduction after acquisitions, and continued research spending. This cash engine gives management flexibility to manage the patent cliff while still investing in the next generation of medicines.
The risks to weigh
The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. Revlimid has already declined under generic entry. The newer portfolio must scale fast enough to offset these losses, which is not guaranteed. Drug pricing pressure (including US Medicare negotiation under the Inflation Reduction Act, which named Eliquis), clinical trial failures, regulatory setbacks, and integration risk from large acquisitions all weigh on the outlook. High debt from dealmaking and litigation exposure add further uncertainty.
Valuation context (as of early 2026)
- Revenue (TTM): ~$48 billion
- Operating margin: ~20% (varies with acquisition charges)
- Net income (TTM): volatile, pressured by large acquisition write-offs
- Dividend yield: ~4-5%
- P/E (TTM): highly variable due to one-time charges; low on a forward adjusted basis
- Free cash flow: ~$13 billion annually
- Net debt: elevated following Karuna and other deals
Bristol Myers tends to trade at a low forward earnings multiple relative to large-cap pharma peers, reflecting market skepticism about its ability to replace patent-cliff revenue. The high dividend yield and strong free cash flow are the bull-case anchors, while the depressed valuation reflects the bear case that legacy declines outrun newer products.
How to decide for yourself
Rather than asking whether BMY is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold BMY indirectly through an index or sector ETF before adding more.
For the full picture, see the BMY stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about BMY against your real portfolio and see your actual exposure before deciding.
Build a basket around BMY with Walnut
Use Bristol Myers Squibb as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is BMY a good stock to buy right now?
+
There is no universal answer. Whether Bristol Myers Squibb fits depends on your thesis, time horizon, risk tolerance, and what you already own. This page lays out the case for, the main risks, and where the stock trades, so you can decide for yourself. Walnut is not an investment adviser and this is not a recommendation.
What does Bristol Myers Squibb do?
+
Large biopharma with oncology and immunology drugs, a high dividend, and a patent-cliff turnaround story.
What are the main risks of BMY?
+
The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. Revlimid has already declined under generic entry. The newer portfolio must scale fast enough to offset these losses, which is not guaranteed. Drug pricing pressure (including US Medicare negotiation under the Inflation Reduction Act, which named Eliquis), clinical trial failures, regulatory setbacks, and integration risk from large acquisitions all weigh on the outlook. High debt from dealmaking and litigation exposure add further uncertainty.
What is BMY's ticker symbol?
+
BMY, listed on the New York Stock Exchange. The company is Bristol Myers Squibb, headquartered in New York City. It trades during US market hours and is available at every major US brokerage.
What does Bristol Myers Squibb do?
+
Bristol Myers Squibb develops, manufactures, and sells branded prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. Key products include Eliquis, Opdivo, Sotyktu, Camzyos, and Cobenfy. It makes money selling patented drugs globally and grows through its pipeline and acquisitions.
Who are Bristol Myers Squibb's main competitors?
+
In oncology, Merck, Roche, AstraZeneca, and Pfizer. In immunology, AbbVie, Amgen, and Eli Lilly. In cardiovascular, Johnson and Johnson and Bayer. Bristol competes broadly across large-cap biopharma.
Why does BMY have such a high dividend yield?
+
Bristol Myers generates substantial free cash flow and has a long history of paying and raising its dividend, producing a yield in the ~4-5% range as of early 2026. The relatively high yield also reflects a depressed share valuation tied to patent-cliff concerns, which mathematically raises the yield.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell BMY; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.